Table 4.
Multivariable analysis of OS and BCSS in OBC patients
| Variables | OS | BCSS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age (year) | ||||||
| < 40 | Reference | |||||
| 40–49 | 0.57 | 0.27–1.19 | 0.13 | 0.64 | 0.26–1.56 | 0.32 |
| 50–59 | 0.82 | 0.43–1.58 | 0.56 | 0.82 | 0.36–1.85 | 0.64 |
| 60–69 | 1.04 | 0.55–1.99 | 0.90 | 0.97 | 0.43–2.18 | 0.93 |
| ≥ 70 | 2.15 | 1.13–4.08 | 0.02 | 1.52 | 0.67–3.41 | 0.31 |
| Race | ||||||
| White | Reference | Reference | ||||
| Black | – | – | – | 0.90 | 0.56–1.47 | 0.68 |
| Asian or Pacific Islander | – | – | – | 0.39 | 0.16–0.97 | 0.04 |
| American Indian/Alaska Native | – | – | – | 4.25 | 1.01–17.99 | 0.05 |
| Unknown/other | – | – | – | 1.23 × 10–6 | 0-INF | 0.99 |
| Marital status | ||||||
| Not married | Reference | – | – | – | ||
| Married | 0.80 | 0.62–1.02 | 0.07 | – | – | – |
| Unknown | 1.25 | 0.68–2.31 | 0.48 | – | – | – |
| Grade | ||||||
| I/II | Reference | Reference | ||||
| III | 0.90 | 0.51–1.59 | 0.71 | 1.71 | 0.65–4.47 | 0.27 |
| IV | 0.66 | 0.22–2.04 | 0.47 | 0.65 | 0.07–5.73 | 0.70 |
| Unknown | 0.70 | 0.41–1.19 | 0.18 | 1.26 | 0.50–3.16 | 0.63 |
| N | ||||||
| N1mi | Reference | Reference | ||||
| N1 | 1.34 × 1011 | 0-INF | 0.99 | 1.17 × 1013 | 0-INF | 1.00 |
| N2 | 1.72 × 106 | 0-INF | 0.99 | 4.04 × 107 | 0-INF | 1.00 |
| N3 | 3.44 | 0.79–14.92 | 0.10 | 4.47 | 0.58–34.38 | 0.15 |
| No. of positive LN | ||||||
| 1–3 | Reference | Reference | ||||
| 4–9 | 2.09 | 1.17–3.73 | 0.01 | 1.96 | 0.95–4.02 | 0.07 |
| ≥ 10 | 1.53 | 0.86–2.73 | 0.15 | 2.28 | 1.16–4.46 | 0.02 |
| Other/Unknown | 2.47 | 1.76–3.47 | < 0.001 | 3.26 | 2.07–5.13 | < 0.001 |
| Stage | ||||||
| IB | Reference | Reference | ||||
| IIA | 1.39 × 10–11 | 0-INF | 0.99 | 1.45 × 10–13 | 0-INF | 1.00 |
| IIIA | 9.80 × 10–7 | 0-INF | 0.99 | 6.46 × 10–8 | 0-INF | 1.00 |
| IIIC | NA | NA | NA | NA | NA | NA |
| Radiation | ||||||
| None/Unknown | Reference | Reference | ||||
| Yes | 0.68 | 0.52–0.88 | 0.003 | 0.63 | 0.45–0.88 | 0.007 |
| Chemotherapy | ||||||
| Yes | Reference | Reference | ||||
| No/Unknown | 0.87 | 0.52–1.44 | 0.59 | 1.08 | 0.51–2.28 | 0.84 |
| Type of systemic therapy | ||||||
| Neoadjuvant | Reference | Reference | ||||
| Adjuvant | 0.93 | 0.58–1.50 | 0.77 | 1.00 | 0.57–1.75 | 0.99 |
| Neoadjuvant + adjuvant | 0.50 | 0.23–1.10 | 0.08 | 0.69 | 0.30–1.59 | 0.38 |
| Only systemic therapy, no surgery | 1.88 | 0.90–3.90 | 0.09 | 2.40 | 1.03–5.60 | 0.04 |
| Other | 0.55 | 0.32–0.96 | 0.04 | 0.46 | 0.23–0.93 | 0.03 |
| No/Unknown | 1.02 | 0.51–2.06 | 0.95 | 1.23 | 0.48–3.17 | 0.67 |
| Subtypes | ||||||
| Luminal A | Reference | Reference | ||||
| Luminal B | 0.63 | 0.31–1.31 | 0.22 | 0.65 | 0.26–1.60 | 0.35 |
| HER2 positive | 1.10 | 0.54–2.22 | 0.79 | 1.31 | 0.56–3.02 | 0.53 |
| Triple negative | 1.42 | 0.81–2.50 | 0.22 | 1.66 | 0.81–3.40 | 0.17 |
| Unknown | 1.53 | 1.02–2.27 | 0.04 | 1.64 | 0.97–2.76 | 0.06 |
| ER | ||||||
| Negative | Reference | Reference | ||||
| Borderline/Unknown | 1.13 | 0.51–2.54 | 0.76 | 1.63 | 0.63- 4.18 | 0.31 |
| Positive | 0.78 | 0.53–1.14 | 0.20 | 0.87 | 0.52–1.43 | 0.57 |
| PR | ||||||
| Negative | Reference | Reference | ||||
| Borderline/Unknown | 0.85 | 0.41–1.79 | 0.68 | 0.72 | 0.29–1.74 | 0.46 |
| Positive | 0.99 | 0.69–1.43 | 0.98 | 0.78 | 0.49–1.24 | 0.30 |
BCSS breast cancer-specific survival, CI confidence interval, ER estrogen receptor, HR hazard ratio, INF infinite, N N staging of OBC, NA not available, OS overall survival, PR progesterone receptor